Clinical trial
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic…
NCT00216060 · Christopher Sweeney, MBBS, Other · Terminated
Key facts
| NCT number | NCT00216060 |
|---|---|
| Title | Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41 |
| Lead sponsor | Christopher Sweeney, MBBS, Other |
| Collaborators | Sanofi Industry Walther Cancer Institute Hoosier Cancer Research Network |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Risedronate, Placebo |
| Enrollment | 63 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | May 26, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- 10–99 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: